1. Home
  2. NSP vs NRIX Comparison

NSP vs NRIX Comparison

Compare NSP & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insperity Inc.

NSP

Insperity Inc.

HOLD

Current Price

$46.59

Market Cap

1.8B

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$18.78

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSP
NRIX
Founded
1986
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
NSP
NRIX
Price
$46.59
$18.78
Analyst Decision
Hold
Strong Buy
Analyst Count
3
13
Target Price
$47.67
$29.08
AVG Volume (30 Days)
974.6K
1.2M
Earning Date
02-09-2026
02-12-2026
Dividend Yield
5.14%
N/A
EPS Growth
N/A
N/A
EPS
0.45
N/A
Revenue
$6,757,000,000.00
$83,687,000.00
Revenue This Year
$4.71
$59.40
Revenue Next Year
$6.40
N/A
P/E Ratio
$104.43
N/A
Revenue Growth
3.19
48.32
52 Week Low
$31.00
$8.18
52 Week High
$95.98
$22.50

Technical Indicators

Market Signals
Indicator
NSP
NRIX
Relative Strength Index (RSI) 68.83 52.54
Support Level $44.82 $18.12
Resistance Level $48.14 $20.18
Average True Range (ATR) 1.81 1.04
MACD 0.25 -0.08
Stochastic Oscillator 85.61 55.83

Price Performance

Historical Comparison
NSP
NRIX

About NSP Insperity Inc.

Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: